Northwest Biotherapeutics Announces Presentations On DCVax®-L Personalized Vaccines, Manufacturing and Scale-Up, and DCVax®-L Clinical Program – QNT Press Release


BETHESDA, Md., June 5, 2022 /PRNewswire/ — Northwest Biotherapeutics (OTCQB:NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that yesterday on June 4, 2022in the Industry Expert Theater during the ASCO 2022 conference, Dr. Marnix Bosch made a presentation discussing the Company’s DCVax-L technology for personalized dendritic cell vaccines, the Sawston, UK facility, the manufacturing technology, the development of automation, and preparations for manufacturing scale-up. In addition, a video presentation about the DCVax®- L clinical program was screened in the Company’s exhibit booth in the ASCO Exhibit Hall.

These presentations are now…

Full story available on Benzinga.com



Source link

Recommended For You

About the Author: News Center